Market Trends of Global Breast Cancer Screening Test Industry
This section covers the major market trends shaping the Breast Cancer Screening Test Market according to our research experts:
Mammograms segment is Expected to Dominate in the Breast Cancer Screening Test Market
The imaging test is the most commonly used screening test for breast cancer, which is considered the most reliable. Mammograms are the most widely used tests to screen for breast cancer. Since mammography is the standard technique for screening breast cancer, governments and other healthcare organizations worldwide are taking initiatives to improve access to women between 50 and 75. For instance, according to the National Cancer Institute (NCI), Updated in October 2021, The NCI is funding the tomosynthesis mammographic imaging screening trial (TMIST), a large-scale randomized breast screening trial that will compare the number of advanced cancers detected in women screened for five years with 3-D mammography to the number detected in women screened with 2-D mammography.
Furthermore, digital breast tomosynthesis can increase mammography's diagnostic accuracy and is used to assess equivocal or suspicious mammography findings. 3-D mammography, often known as breast tomosynthesis, is a new technology. This process combines photos from various angles around the breast to create a 3-D-like image. This technology is becoming more widely available in clinics. Such advancements will drive market growth due to higher adoption across the world.
The favorable initiatives related to mammograms are also expected to boost segment growth. For instance, as per the government's national screening program in Australia, Breast Screen Australia, women aged 50-74 need to undergo free mammograms every two years. Cancer Australia, in September 2020, released a set of regulations where breast imaging for early diagnosis in the initial stages of breast cancer was discussed.
In May 2022, VolparaHealth introduced updated products for its integrated platform to deliver personalized breast care at the SBI/ACR Breast Imaging Symposium 2022. Volpara's AI-driven breast software tools improve mammography quality and reporting, volumetric breast density measurements, and cancer risk assessment. Such developments by market players assist in accelerating market growth.
North America Dominates the Market and Expected to do Same in the Forecast Period
In the North American region, the United States holds the largest market share. This can be majorly attributed to the increasing incidence rates of breast cancer and rising awareness among the population for the early detection of cancer. The presence of the developed healthcare infrastructure is expected to propel the market in the United States.
According to the news published in May 2022, as part of a goal to achieve "zero fatalities from breast cancer" by 2030, the United States National Breast Cancer Foundation (NBCF) announced funding of over USD 12.4 million for 20 research initiatives. Such goals to reduce breast cancer are expected to drive the growth of the market studied over the forecast period in this region.
Also, as per Canadian Medical Association Journal, May 2022 report, an estimated 28,600 new breast cancer cases were estimated to occur in Canada in 2022, accounting for 25% of total new cancer diagnosed in women in Canada in 2022.
Moreover, awareness campaigns and free breast cancer screening camps in the region are also expected to propel the market growth during the forecast period. For instance, in October 2022, Pennsylvania Hospital partnered with the American Cancer Society, the Consulate of Mexico in Philadelphia, and Univision 65 to host an annual breast cancer screening event, by providing free mammograms to uninsured and underinsured women in the Philadelphia community.
Therefore, owing to the above-mentioned factors, the breast cancer screening market is expected to drive in North America over the forecast period.
